Roche devotes some R&D to manufacturing; UPS starts door-to-door cold chain in Asia;

> At Roche's newly opened R&D center in Switzerland, some researchers will focus on such manufacturing processes as processing new active ingredients into tablets, capsules and injectable dosage forms in vials and pre-filled syringes. News

> UPS ($UPS) has launched Temperature True, a door-to-door cold chain transportation and monitoring service in Asia, and PharmaPort 360, an airfreight container for healthcare cold chain transportation. Story

> Photonz has transferred its strain and fermentation process for producing the omega-3 fatty acid, eicosapentaenoic acid (EPA), to a contract manufacturer, moving a step closer to commercial manufacturing by fermentation. Report

> DHL Global Forwarding has signed a master lease agreement with container provider CSafe, broadening its offerings for temperature-controlled shipments. DHL release

> BioMarin Pharmaceutical ($BMRN) will double the capacity of its Novato, CA, plant to produce $1 billion in products, including its biggest seller Naglazyme. Item

> Despite preliminary interest from such big-name shippers as FedEx ($FDX) and DHL, Hyderabad is not likely to become the much-needed cargo hub for Indian drugs and other products because of its location and lack of manufacturing base, says an unnamed analyst. Story

> Novavax ($NVAX) plans a doubling of production capacity with its planned move to Gaithersburg, MD, to better handle a recent $179 million federal contract to develop seasonal and pandemic flu vaccines. Story

> Six drug-delivery technologies are helping drugmakers extend patents: affinity-based targeting, controlled/sustained-release systems, passive delivery, active device delivery, passive device delivery and processing technologies. Release

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.